# Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

> **NCT04278872** · PHASE2 · TERMINATED · sponsor: **Sojournix, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Hot Flashes

## Interventions

- **DRUG:** SJX-653
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04278872
- **Lead sponsor:** Sojournix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-09
- **Primary completion:** 2021-02-12
- **Final completion:** 2021-04-07
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The study was terminated early as the goal of determining a safe and efficacious dose for further development for the treatment of VMS was not met
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04278872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04278872, "Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04278872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*